Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
The research grade Briakinumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype: Human IgG1 lambda.
Source: The anti-human IL-12 / IL-23 monoclonal antibody briakinumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade briakinumab biosimilar specifically binds to the human interleukin-12 (IL-12) and interleukin-23 (IL-23).
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by briakinumab.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: <1 EU/mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The research grade briakinumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
Background
What is Briakinumab Biosimilar research grade? Briakinumab is a human anti-IL-12 / IL-23 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders. Briakinumab Biosimilar uses the same protein sequences as the therapeutic antibody briakinumab.
Syd Labs also provides the following anti-IL antibody biosimilar proteins:
Pascolizumab Biosimilar, research grade, anti-human IL-4 monoclonal antibody
Sarilumab Biosimilar, research grade, anti-human IL-6/IL-6R monoclonal antibody
Secukinumab Biosimilar, research grade, anti-human IL-17/IL-17a monoclonal antibody
Tocilizumab Biosimilar, research grade, anti-human IL-6/IL-6R monoclonal antibody
Ustekinumab Biosimilar, research grade, anti-human IL-12/IL-23 monoclonal antibody
Copyright © 2009-2025 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.
Friend Link: Ushelf